- Pharma Equity Group's subsidiary, Reponex Pharmaceuticals A/S, received regulatory approval on **September 1, 2025**, to initiate a pivotal Phase 2 clinical trial for its drug candidate **RNX-011**.  **[1808158_422b3809334e41d9bce40b389060e1dd_0]** 
- The study will investigate RNX-011 for the treatment of **secondary peritonitis**, a serious and life-threatening intra-abdominal infection.  **[1808158_422b3809334e41d9bce40b389060e1dd_0]** 
- The trial is designed to demonstrate that RNX-011 can **reduce serious postoperative complications** and is expected to enroll **32 patients**, with the first patient anticipated in **Q4 2025**.  **[1808158_422b3809334e41d9bce40b389060e1dd_0]** 
- This approval is considered a **crucial commercial milestone** for Pharma Equity Group, strengthening its position for upcoming partner dialogues.  **[1808158_422b3809334e41d9bce40b389060e1dd_0]**

Repare Therapeutics (RPTX)